nach oben

Current Hematologic Malignancy Reports

Erschienen in:

05.09.2016 | Myelodysplastic Syndromes (D Steensma, Section Editor)

Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts

verfasst von: Anna Mies, Olivier Hermine, Uwe Platzbecker

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Distinct subtypes of lower risk myelodysplastic syndromes display ring sideroblasts in the bone marrow, i. e., erythroid progenitors characterized by excessive iron deposited in the mitochondria. This morphological feature is frequently associated with somatic mutations in components of the splicing machinery that constitutes the underlying molecular principle of the disease. Conventional treatment regimen with erythropoiesis-stimulating agents often fails to induce sustained erythroid improvement in these patients that harbor defects in late-stage erythroblasts downstream of erythropoietin action. In the present review, we will discuss activin receptor ligand traps as novel therapeutic strategies particularly for sideroblastic subgroups of myelodysplastic syndromes that were recently shown to alleviate anemia by specifically inhibiting aberrant TGF-β signaling and thereby promoting erythroid differentiation.

Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol. 2015;90(6):549–59.CrossRefPubMed

2.•

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. Revised WHO classification of MDS including re-categorization of MDS-RS.CrossRefPubMed

Malcovati L, Cazzola M. Refractory anemia with ring sideroblasts. Best Pr Res Clin Haematol. 2013;26(4):377–85.CrossRef

Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594–603.CrossRefPubMed

Jeromin S, Haferlach T, Weissmann S, Meggendorfer M, Eder C, Nadarajah N, et al. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. Haematologica. 2015;100(4):e125–7.CrossRefPubMedPubMedCentral

Broséus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013;27(9):1826–31.CrossRefPubMed

Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012;120(16):3173–86.CrossRefPubMedPubMedCentral

Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384–95.CrossRefPubMedPubMedCentral

Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239–46.CrossRefPubMedPubMedCentral

10.

Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012;119(2):569–72.CrossRefPubMedPubMedCentral

11.

Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–9.CrossRefPubMed

12.

Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood. 2012;119(24):5674–7.CrossRefPubMed

13.

Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126(2):233–41.CrossRefPubMedPubMedCentral

14.

Nikpour M, Scharenberg C, Liu A, Conte S, Karimi M, Mortera-Blanco T, et al. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia. 2013;27(4):889–96.CrossRefPubMed

15.

Boultwood J, Pellagatti A, Nikpour M, Pushkaran B, Fidler C, Cattan H, et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One. 2008;3(4), e1970.CrossRefPubMedPubMedCentral

16.

Del Rey M, Benito R, Fontanillo C, Campos-Laborie FJ, Janusz K, Velasco-Hernández T, et al. Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts. PLoS One. 2015;10(5), e0126555.CrossRefPubMedPubMedCentral

17.

Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, Attwood M, et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia. 2015;29(5):1092–103.CrossRefPubMed

18.

Conte S, Katayama S, Vesterlund L, Karimi M, Dimitriou M, Jansson M, et al. Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts. Br J Haematol. 2015;171(4):478–90.CrossRefPubMedPubMedCentral

19.

Obeng EA, McConkey ME, Campagna DR, Schneider RK, Chen MC, Schmidt PJ, et al. Mutant splicing factor 3b subunit 1 (SF3B1) causes dysregulated erythropoiesis and a stem cell disadvantage. Blood. 2014;124:828.CrossRef

20.

Ambaglio I, Malcovati L, Papaemmanuil E, Laarakkers CM, Della Porta MG, Gallì A, et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica. 2013;98(3):420–3.CrossRefPubMedPubMedCentral

21.

Zhu Y, Li X, Chang C, Xu F, He Q, Guo J, et al. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis. Leuk Res. 2016;44:8–16.CrossRefPubMed

22.•

Mian SA, Rouault-Pierre K, Smith AE, Seidl T, Pizzitola I, Kizilors A, et al. SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment. Nat Commun. 2015;6:10004. Elegant study demonstrating that SF3B1 mutations are an initiating event during clonal evolution in MDS-RS.CrossRefPubMedPubMedCentral

23.

Raaijmakers MHGP, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464(7290):852–7.CrossRefPubMedPubMedCentral

24.

Balderman S, Calvi L. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome. Blood. 2016;127(5):616–25.CrossRefPubMedPubMedCentral

25.

Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376–82.CrossRefPubMedPubMedCentral

26.

Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153–8.CrossRefPubMedPubMedCentral

27.•

Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–27. Description of the role of acquired mutations in MDS, in particular RNA splicing mutations as driver mutations for disease progression.CrossRefPubMedPubMedCentral

28.

Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer. 2008;112(5):1089–95.CrossRefPubMed

29.•

Fenaux P, Ades L. How we treat lower-risk myelodysplastic syndromes. Blood. 2013;121(21):4280–6. Review summarizing current treatment options for lower risk MDS patients.CrossRefPubMed

30.

Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol. 1995;89(1):67–71.CrossRefPubMed

31.

Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2008;87(7):527–36.CrossRefPubMed

32.

Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114(12):2393–400.CrossRefPubMedPubMedCentral

33.

Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005;106(3):803–11.CrossRefPubMed

34.

Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(1):97–108.CrossRefPubMed

35.

Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32.CrossRefPubMedPubMedCentral

36.

Prébet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–7.CrossRefPubMedPubMedCentral

37.

Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Párez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579–85.CrossRefPubMed

38.

Platzbecker U, Mufti G. Allogeneic stem cell transplantation in MDS: how? When? Best Pract Res Clin Haematol. 2013;26(4):421–9.CrossRefPubMed

39.

Aul C, Arning M, Runde V, Schneider W. Serum erythropoietin concentrations in patients with myelodysplastic syndromes. Leuk Res. 1991;15(7):571–5.CrossRefPubMed

40.

Hattangadi SM, Wong P, Zhang L, Flygare J, Lodish HF. From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood. 2011;118(24):6258–68.CrossRefPubMedPubMedCentral

41.

Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood. 2002;99(5):1594–601.CrossRefPubMed

42.

Hellström-Lindberg E, van de Loosdrecht A. Erythropoiesis stimulating agents and other growth factors in low-risk MDS. Best Pract Res Clin Haematol. 2013;26(4):401–10.CrossRefPubMed

43.

Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. 2015;9:4479–99.PubMedPubMedCentral

44.

Mies A, Bulycheva E, Rogulj IM, Hofbauer LC, Platzbecker U. Alterations within the osteo-hematopoietic niche in MDS and their therapeutic implications. Curr Pharm Des. 2016;22(16):2323–32.CrossRefPubMed

45.

Blank U, Karlsson S. TGF-β signaling in the control of hematopoietic stem cells. Blood. 2015;125(23):3542–50.CrossRefPubMed

46.

Zermati Y, Fichelson S, Valensi F, Freyssinier JM, Rouyer-Fessard P, Cramer E, et al. Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors. Exp Hematol. 2000;28(8):885–94.CrossRefPubMed

47.

Xie Y, Bai H, Liu Y, Hoyle DL, Cheng T, Wang ZZ. Cooperative effect of erythropoietin and TGF-β inhibition on erythroid development in human pluripotent stem cells. J Cell Biochem. 2015;116(12):2735–43.CrossRefPubMed

48.••

Suragani RNVS, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408–14. First experimental evidence for efficacy of ACE/RAP-536 in MDS.CrossRefPubMed

49.

Lin YW, Slape C, Zhang Z, Aplan PD. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood. 2005;106(1):287–95.CrossRefPubMedPubMedCentral

50.

Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Gundabolu K, et al. Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS. Blood. 2008;112(8):3434–43.CrossRefPubMedPubMedCentral

51.

Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, et al. MiR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood. 2013;121(15):2875–81.CrossRefPubMedPubMedCentral

52.

Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, et al. Reduced SMAD7 leads to overactivation of TGF-β signaling in MDS that can be reversed by a specific inhibitor of TGF-β receptor I kinase. Cancer Res. 2011;71(3):955–63.CrossRefPubMed

53.

Raje N, Vallet S. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther. 2010;12(5):586–97.PubMed

54.

Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J, et al. A soluble activin receptor type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in cynomolgus monkeys. Bone. 2010;46(4):1082–8.CrossRefPubMed

55.

Fajardo RJ, Manoharan RK, Pearsall RS, Davies MV, Marvell T, Monnell TE, et al. Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone. 2010;46(1):64–71.CrossRefPubMed

56.

Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci U S A. 2008;105(19):7082–7.CrossRefPubMedPubMedCentral

57.

Mulivor AW, Barbosa D, Kumar R, Sherman ML, Seehra JS, Pearsall RS. RAP-011, a soluble activin receptor type IIa murine IgG-Fc fusion protein, prevents chemotherapy induced anemia. Blood. 2009;114:161.

58.

Dussiot M, Maciel TT, Fricot A, Chartier C, Negre O, Veiga J, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nat Med. 2014;20(4):398–407.CrossRefPubMed

59.

Carrancio S, Markovics J, Wong P, Leisten J, Castiglioni P, Groza MC, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014;165(6):870–82.CrossRefPubMedPubMedCentral

60.

Langdon JM, Barkataki S, Berger AE, Cheadle C, Xue Q-L, Sung V, et al. RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice. Am J Hematol. 2015;90(1):8–14.CrossRefPubMed

61.

Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2009;24(4):744–52.CrossRefPubMed

62.

Sherman ML, Borgstein NG, Mook L, Wilson D, Yang Y, Chen N, et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J Clin Pharmacol. 2013;53(11):1121–30.PubMed

63.

Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014;165(6):814–23.CrossRefPubMedPubMedCentral

64.

Iancu-Rubin C, Mosoyan G, Wang J, Kraus T, Sung V, Hoffman R. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013;41(2):155–66.e17.

65.

Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, et al. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016;24(4):1517–25.CrossRefPubMed

66.

Komrokji RS, Garcia-Manero G, Ades L, Laadem A, Vo B, Prebet T, et al. An open-label, phase 2, dose-finding study of sotatercept (ACE-011) in patients with low or intermediate-1 (int-1) myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML) and anemia requiring transfusion. Blood. 2014;124:3251.

67.

Attie KM, Allison MJ, Mcclure T, Boyd IE, Wilson DM, Pearsall AE, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766–70.CrossRefPubMedPubMedCentral

68.

Platzbecker U, Giagounidis A, Germing U, Götze K, Kiewe P, Mayer K, et al. Luspatercept increases hemoglobin and reduces transfusion burden in patients with low-intermediate risk myelodysplastic syndromes (MDS): long-term results from phase 2 PACE-MDS study. Haematologica. 2016;S131.

69.

Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, et al. Luspatercept (ACE-536) reduces disease burden, including anemia, iron overload, and leg ulcers, in adults with beta-thalassemia: results from a phase 2 study. Blood. 2015;126:752.

Titel: Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts
verfasst von: Anna Mies
Olivier Hermine
Uwe Platzbecker
Publikationsdatum: 05.09.2016
Verlag: Springer US
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 6/2016
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-016-0347-9

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Sézary Syndrome: Clinical and Biological Aspects

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Antibody-Based Treatment of Acute Myeloid Leukemia

Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases

Assessing Quality of Care for the Myelodysplastic Syndromes

Molecular Testing in Patients with Suspected Myelodysplastic Syndromes

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie